Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients

被引:185
作者
Murray, Thomas S.
Egan, Marie
Kazmierczak, Barbara I.
机构
[1] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Microbial Pathogenesis, New Haven, CT 06520 USA
[3] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA
关键词
biofilm; cystic fibrosis; Pseudomonas aeruginosa; quorum-sensing;
D O I
10.1097/MOP.0b013e3280123a5d
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Purpose of review Chronic infection with Pseudomonas aeruginosa is a leading cause of morbidity and mortality in individuals with cystic fibrosis despite the aggressive use of antibiotics. P. aeruginosa employs a number of strategies that promote chronic pulmonary colonization instead of acute infection. These include biofilm formation, evasion of he host immune system, and conversion to a mucoid phenotype. This review discusses recent advances regarding P. aeruginosa pathogenesis and biofilm behavior in the setting of chronic pulmonary disease. Recent findings Biofilm formation in the cystic fibrosis lung likely occurs under anaerobic conditions, is controlled by bacterial quorum-sensing mechanism, and is enhanced by environmental components in the cystic fibrosis airway. P. aeruginosa possesses regulatory pathways that recognize environmental cues to favor either acute infection or chronic colonization. P. aeruginosa that inhabit the respiratory tract accumulate mutations favoring chronic colonization. Azithromycin, a macrolide with clinical benefit in cystic fibrosis, alter P. aeruginosa biofilm formation include molecules that disrupt quorum sensing. Summary Eradication of P. aeruginosa in cystic fibrosis patients remains problematic. As more information emerges about P. aeruginosa behavior in vivo, potential therapeutics directed against biofilms and mucoid P. aeruginosa are being developed.
引用
收藏
页码:83 / 88
页数:6
相关论文
共 56 条
[31]   Risk factors for initial acquisition of Pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screening [J].
Maselli, JH ;
Sontag, MK ;
Norris, JM ;
MacKenzie, T ;
Wagener, JS ;
Accurso, FJ .
PEDIATRIC PULMONOLOGY, 2003, 35 (04) :257-262
[32]  
NALA Y, 2006, ANTIMICROB AGENTS CH, V50, P1680
[33]   Evolving stealth:: Genetic adaptation of Pseudomonas aeruginosa during cystic fibrosis infections [J].
Nguyen, Dao ;
Singh, Pradeep K. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (22) :8305-8306
[34]   Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis [J].
Nixon, GM ;
Armstrong, DS ;
Carzino, R ;
Carlin, JB ;
Olinsky, A ;
Robertson, CF ;
Grimwood, K .
JOURNAL OF PEDIATRICS, 2001, 138 (05) :699-704
[35]   Cystic fibrosis sputum supports growth and cues key aspects of Pseudomonas aeruginosa physiology [J].
Palmer, KL ;
Mashburn, LM ;
Singh, PK ;
Whiteley, M .
JOURNAL OF BACTERIOLOGY, 2005, 187 (15) :5267-5277
[36]   Role of the cystic fibrosis transmembrane conductance regulator in innate immunity to Pseudomonas aeruginosa infections [J].
Pier, GB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (16) :8822-8828
[37]   Understanding the control of Pseudomonas aeruginosa alginate synthesis and the prospects for management of chronic infections in cystic fibrosis [J].
Ramsey, DM ;
Wozniak, DJ .
MOLECULAR MICROBIOLOGY, 2005, 56 (02) :309-322
[38]  
RAMUSSEN TB, 2006, INT J MED MICROBIOL, V296, P149
[39]   Pseudomonas acquisition in young patients with cystic fibrosis:: pathophysiology, diagnosis, and management [J].
Rosenfeld, M ;
Ramsey, BW ;
Gibson, RL .
CURRENT OPINION IN PULMONARY MEDICINE, 2003, 9 (06) :492-497
[40]   Pathogen-host interactions in Pseudomonas aeruginosa pneumonia [J].
Sadikot, RT ;
Blackwell, TS ;
Christman, JW ;
Prince, AS .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 171 (11) :1209-1223